Education
About Us
Working with TipRanks
Follow Us
Margaret Mcglynn Insider Profile
4 Followers
Margaret Mcglynn, Director at Amicus, holds 25.59K shares in Novavax (Ticker: NVAX), holds 91.55K shares in Amicus (Ticker: FOLD), holds 178.00 shares in Vertex Pharmaceuticals (Ticker: VRTX).
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
-4.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Margaret Mcglynn holds in companies
Most Profitable Insider Trade
The most profitable trade made by Margaret Mcglynn
Margaret Mcglynn's Trading History
Amicus
Jun 06, 2025
Director
Uninformative Buy
―
$812.05K
Novavax
Jun 16, 2025
Director
Uninformative Buy
74.50K
$190.37K
Vertex Pharmaceuticals
May 03, 2022
Director
Uninformative Sell
―
$72.89K
Air Products and Chemicals
―
Director
―
$0.00
List of latest transactions for each holding click on a transaction to see Margaret Mcglynn's performance on stock
You May Also Like
Margaret Mcglynn insider profile FAQ
What is the percentage of profitable transactions made by Margaret Mcglynn?
The percentage of profitable transactions made by Margaret Mcglynn is 33%.
What is the average return per transaction made by Margaret Mcglynn?
The average return per transaction made by Margaret Mcglynn is -4.90%.
What stocks does Margaret Mcglynn hold?
Margaret Mcglynn holds: FOLD, NVAX, VRTX, APD stocks.
What was Margaret Mcglynn’s latest transaction?
Margaret Mcglynn latest transaction was an Uninformative Buy of $74.50K.
What was Margaret Mcglynn's most profitable transaction?
Margaret Mcglynn’s most profitable transaction was an Informative Sell of FOLD stock on March 6, 2024. The return on the trade was 28.40%.
What is Margaret Mcglynn's role in Amicus?
Margaret Mcglynn's role in Amicus is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.